- Kowa
Kowa Announces First EU Marketing Authorisation for Pitavastatin Granted in the UK
Wokingham, England, August 17, 2010 (ots/PRNewswire) - Kowa are delighted to announce that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a UK licence for their statin, Livazo(R) (pitavastatin)....
- 17.08.2010, 16:34:33
- /
- OTE0007
- Kowa
Pitavastatin Demonstrates Sustained Efficacy, Tolerability and LDL-C Target Attainment Over 52 Weeks
Wokingham, England, April 28, 2010 (ots/PRNewswire) - New long-term phase III data published today in Atherosclerosis demonstrates that, of patients with primary hypercholesterolaemia or combined dyslipidaemia who...
- 28.04.2010, 14:01:09
- /
- OTE0014
- Kowa
Pitavastatin Demonstrates no Significant Drug-to-Drug Interaction When Administered With CYP3A4 Inhibitors
Barcelona, Spain (ots/PRNewswire) -
- 02.09.2009, 08:37:05
- /
- OTE0002
- Kowa
Pitavastatin is Non-Inferior to Atorvastatin and Simvastatin and Demonstrates Sustained Efficacy and Tolerability Over 52 Weeks
Barcelona, Spain (ots/PRNewswire) -
- 01.09.2009, 14:14:08
- /
- OTE0004
Alle Aussendungen
Alle Anhänge
